Markets & Stocks

Stock quotes, market indicators and the latest market news.

Market Summary Market News Stock Quotes Market Movers

Recent Quotes

View Full List

My Watchlist

Indicators

Local Stocks

Markets:

Overview

News

Currencies

International

Treasuries

Organon & Co. Common Stock (NY:OGN)

13.79 -0.02 (-0.11%)

Delayed Quote Updated: 1:33 PM EDT, Oct 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Organon & Co. Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Organon Expects Lower EBITDA Margin For FY22, Clocks Mixed Q2 Earnings ↗

August 04, 2022

Via Benzinga

Organon: Q2 Earnings Insights ↗

August 04, 2022

Organon (NYSE:OGN) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Organon reported in-line EPS of $1.25...

Via Benzinga

Organon Reports Results for the Second Quarter Ended June 30, 2022

August 04, 2022

From Organon & Co.

Via Business Wire

Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate

July 28, 2022

From Organon & Co.

Via Business Wire

Organon To Report Second Quarter Results and Host Conference Call on August 4, 2022

July 21, 2022

From Organon & Co.

Via Business Wire

Amphastar's Generic Ganirelix Acetate Injection Scores FDA Approval ↗

April 08, 2022

Via Benzinga

Merck Spinoff Organon Beats Quarterly Views, But Offers Dim Guidance ↗

February 17, 2022

Organon's sales and earnings fell less than expected, but 2022 sales guidance missed.

Via Investor's Business Daily

Week In Review: Joincare Plans $300-$400 Million IPO On Swiss Exchange ↗

June 18, 2022

Joincare Pharmaceutical of Shenzhen plans to list on the SIX Swiss stock exchange, an unusual venue for a China biopharma. The company said it aims to broaden its financing sources and increase global...

Via Talk Markets

Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates

June 13, 2022

From Organon & Co.

Via Business Wire

On One Year Anniversary, Organon Introduces Global ESG Strategy and Commitments with Publication of Inaugural ESG Report

June 02, 2022

From Organon & Co.

Via Business Wire

Earnings Scheduled For February 17, 2022 ↗

February 17, 2022

Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million.

Via Benzinga

Market Selloff ↗

May 10, 2022

In a U.S. market selloff, the strong performance of mostly foreign issues was impressive.

Via Talk Markets

Organon Easily Beats First-Quarter Expectations Despite Nexplanon Slip-Up ↗

May 05, 2022

The firm's biggest product sustained a hit due to exchange rates and buying patterns.

Via Investor's Business Daily

Organon Reports Results for the First Quarter Ended March 31, 2022

May 05, 2022

From Organon & Co.

Via Business Wire

Organon To Report First Quarter Results and Host Conference Call on May 5, 2022

April 21, 2022

From Organon & Co.

Via Business Wire

Organon Inks Licensing Pact For Daré Bioscience's Bacterial Vaginosis Treatment ↗

March 31, 2022

Organon & Co (NYSE: OGN)

Via Benzinga

Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV)

March 31, 2022

From Organon & Co.

Via Business Wire

Healthy Pharma Favorites ↗

March 25, 2022

Here's a look at two drug makers that we recommend in our Growth & Income Portfolio. The stocks in this portfolio are generally higher-quality, larger-cap companies that have fallen out of favor.

Via Talk Markets

AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar ↗

March 09, 2022

Alvotech Holdings S.A. has entered into a settlement agreement with AbbVie Inc (NYSE: ABBV), allowing Alvotech to market AVT02 (100 mg/mL), its high-...

Via Benzinga

Overview Of Value Stocks In The Healthcare Sector ↗

February 21, 2022

What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be...

Via Benzinga

World Markets News For Thursday ↗

February 17, 2022

Ericsson stock lost another 5.27% today in US markets.

Via Talk Markets

Established Brands Hit Organon's Q4 Sales, Expects FY22 Sales Of Upto $6.4B ↗

February 17, 2022

Organon & Co's (NYSE: OGN) Q4 FY21 sales decreased 1% to $1.6 billion, beating the consensus of $1.57 billion. Women's Health increased 6%, driven primarily...

Via Benzinga

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2021

February 17, 2022

From Organon & Co.

Via Business Wire

Organon Acquires Contraceptive Products, Marvelon® and Mercilon®, in the People’s Republic of China, including Hong Kong and Macau, and Agrees to Acquire these Products in Vietnam

February 16, 2022

From Organon & Co.

Via Business Wire

Nuclear Winter ↗

February 11, 2022

Mexico is raising interest rates to 6%, from 5.5%.

Via Talk Markets

Organon antaa koko henkilökunnalleen vapaapäivän oman terveytensä edistämiseksi kansainvälisenä naisten päivänä

February 10, 2022

”Koska Covid-19-pandemialla on edelleen suhteettoman suuri vaikutus naisiin, Organon kutsuu muita organisaatioita liittymään joukkoonsa ja olemaan

Via EIN Presswire

Organon Declares Paid Time Off for All Employees on International Women’s Day; Employees to Focus on Their Own Health in Recognition of Growing Women’s Health Inequity

February 02, 2022

From Organon & Co.

Via Business Wire

Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 17, 2022

February 01, 2022

From Organon & Co.

Via Business Wire

FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate

January 05, 2022

From Organon & Co.

Via Business Wire

Organon To Present at the 40th Annual J.P. Morgan Healthcare Virtual Conference

December 20, 2021

From Organon & Co.

Via Business Wire

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.